Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
临床主要用于敏感菌所致的呼吸道感染,包括社区获得性肺炎、慢性支气管炎、急性上颌窦咽炎及扁桃体炎。
Sanofi-Aventis, Bridgewater, New Jersey, United States
Chosun University Hospital, Gwangju, Jeonnam, Korea, Republic of
Pulmonary Associates PA, Phoenix, Arizona, United States
Sanofi-Aventis, San Jose, Costa Rica
Sanofi-Aventis, Lima, Peru
Sanofi-Aventis, Istanbul, Turkey
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.